Monthly Archives: February 2012

(SACRAMENTO, Calif.) - Experts from UC Davis Health System will share the latest research about regenerative medicine, with a focus on chronic pain and the promise of stem cell therapies, during a community forum on the university's Sacramento campus. The discussion takes place on Tuesday, Feb. 7, from 6- 7:30 p.m. at the UC Davis Education Building, 4610 X Street, in Sacramento. The event features Jan Nolta, director of the UC Davis Institute for Regenerative Cures; Scott Fishman, chief of the UC Davis Division of Pain Medicine; and Kee Kim, chief of spinal neurosurgery at UC Davis Medical Center. The three specialists will discuss the challenges of treating chronic pain, especially back and neck pain, and the clinical research now under way to use stem cell therapies to overcome it. The forum is free and open to the public. It is part of "Stem Cell Dialogues," UC Davis Health System's discussion series about regenerative medicine and the goal of turning stem cells into cures. Each speaker will provide a short presentation followed by a panel discussion and question and answer period. The event will be moderated by Fred Meyers, professor of medicine and pathology, and executive associate dean of UC … Continue reading →

05-09-2011 07:29 They are among the best in their scientific fields. With the series "Brilliant Minds," DW-tv introduces top-notch young researchers from all over the world who live and work in Germany.Rajkumar Thummer does his research at the Life and Brain Center at the University of Bonn, one of the Germany's leading institutes for stem cell research. The 30-year-old Indian is working on ways to transform human cells back into stem cells. By using stem cells, doctors are hoping they can treat conditions like Alzheimer's disease in future. If this could be done by using stem cells from the body, problems such as patient rejection of transplanted tissue or organs could become a thing of the past. See the rest here: Brilliant Minds - Stem Cell Research | Tomorrow Today - Video … Continue reading →

02-02-2012 21:05 Stroke Treatment in Bangalore, Paralysis Treatment in Bangalore, Paralysis Treatment in Bangalore in Karnataka , Paralysis Treatment in Bangalore in Karnataka India , Paralysis Treatment , Stroke Treatment in Bangalore, Stroke Treatment Bangalore in Karnataka , Stroke Treatment in Bangalore Karnataka India , Stroke Treatment , home for aged in bangalore , old age homes, ,vrudhashram in bangalore ,old age homes in bangalore , bangalore old age home , Home For The Aged , home for mentally retarded in bangalore , home for disabled in bangalore ,home for handicapped people in bangalore ,home for mentally challenged in bangalore , home nursing services bangalore , home nurses in bangalore , home nursing , bangalore home nurse , We Provide Good Facility with Food Accommodation 24/7 Nursing care, medical, doctor,hygienic,Good Air , Garden ,Neat and Clean, old age home for movable person and bedridden,disabled people too , http://www.navachaithanya.com , Email ID : kncashramas@gmail.com , Call : Mobile 9448244695 / 9242429994 , Land 080-65655555 ( Please Save and Pass this numbers to All. It may help some one ) Regardsgs Navachaithanya , http://www.navachaithanya.com , http://www.karunaamrutha.com , http://www.dialjusts.com , http://www.karunamrutha.com , http://www.navachaithanyahomenursing.com , http://www.navachaithanyaoldagehome.com , http://www.dialjust.com , http://www.navachatanya.com , http://www.navachaitanya.com , http://www.kncarogyadhama.com … Continue reading →

(RTTNews.com) - Acorda Therapeutics, Inc. (ACOR) presented data showing that treatment with dalfampridine improved motor function in a preclinical model of stroke, with treatment initiated at least four weeks following the ischemic event. "These are the first preclinical data to show an oral pharmacologic treatment can improve function in chronic, or long term, stroke. We are excited by these results and plan to begin proof-of-concept human clinical trials of AMPYRA in people with chronic stroke later this year," said Andrew Blight, Acorda Therapeutics' Chief Scientific Officer. The company said that the presentation reviewed data from three study groups that received treatment beginning four weeks after a permanent middle cerebral artery occlusion. The neurological impairments that result are expected to be permanent by four weeks, which represents the chronic stage of stroke. Researchers assessed functional improvement using a battery of standard motor function tests in both the forelimbs and hind limbs. According to the company, in each of the three study groups, treatment with dalfampridine resulted in significant improvement in function compared to placebo across all measures during the respective treatment periods. Improvements in the high dose phase were consistently better than those seen in the low dose phase. Further, Acorda … Continue reading →

Led by Louisiana State University neurologist Dr. Nicolas Bazan, a team of researchers from several institutions has claimed a potential breakthrough in drug treatment to prevent long-term brain damage in those who suffer certain strokes. Bazan directed a study that, using laboratory rats, administered aspirin and an omega-3 essential fatty acid to yield a new protective molecule that can mitigate damage to cells around the area of an ischemic stroke. Ischemic stroke occurs when an arterial blockage denies oxygenated blood to parts of the brain, as opposed to hemorrhagic stroke, which occurs when a vessel bursts inside the brain. The results, Bazan said, portend a “novel approach for pharmaceutical intervention.” Stroke is the fourth-leading cause of death in the United States and the leading cause of newly acquired disability in adulthood. Bazan presented his findings Thursday at the International Stroke Conference, which concludes Friday at the Ernest N. Morial Convention Center in New Orleans. The study, which was financed by a National Institutes of Health grant, was designed to analyze benefits of neuroprotective agents — long a focus of Bazan’s career — that can help prevent irreversible damage in the stroke-affected area. There is considerable research interest internationally in neuroprotectors … Continue reading →

THURSDAY, Feb. 2 (HealthDay News) -- Greater use of certain types of treatments for kids with sickle cell anemia may explain why black children's risk of ischemic stroke dropped significantly between 1999 and 2007, new research finds. The disparity in stroke-related deaths between black and white children also fell during that period. Prior to 1998, black children were 74 percent more likely to die of ischemic stroke than white children. The racial difference is attributed in part to higher rates of sickle cell anemia, a blood disorder that raises the risk of stroke, among black children, according to the study scheduled to be presented Thursday at the American Stroke Association meeting in New Orleans. Then, in 1998, a major clinical trial found that treatments such as chronic (regularly scheduled) blood transfusions could dramatically lower the risk of stroke among kids with sickle cell anemia who were at high risk of stroke. In the study, researchers reviewed death certificates for U.S. children and young adults under age 20 who died between 1998 and 2007. Between 1999 and 2007, they found risk of ischemic stroke among black children fell significantly, although black children were still 27 percent more likely to have an … Continue reading →

Study Highlights: A new drug, AX200, which produced improvement in an earlier small clinical trial, didn't improve disability among stroke patients when begun within nine hours of the onset of stroke symptoms. Ninety days after treatment, drug and placebo recipients had similar levels of moderate disability. NEW ORLEANS, Feb. 3, 2012 (GLOBE NEWSWIRE) -- A new drug that showed promise in animal studies and an early clinical trial didn't improve disability among stroke patients, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012. After a stroke and other types of brain damage, the brain naturally produces more granulocyte colony stimulating factor (G-CSF). The protein can prevent further cell injury by protecting nerve cells and boosting blood vessel growth. The new drug, AX200, is a manufactured form of G-CSF. Ninety days after treatment, patients receiving AX200 or a placebo both scored a three on the 0-6 modified Rankin scale, a common test for stroke-related disability. In a secondary analysis, also at day 90, researchers assessed patients with the National Institutes of Health Stroke Scale. The difference between the drug and placebo was less than half a point (8.88 on AX200 vs. 8.45 on placebo), which was … Continue reading →

21-06-2011 13:52 Created on June 21, 2011 by Orlando total training Go here to see the original: Rehab Therapy Conditioning for Ataxia Condition - Video … Continue reading →